Provided herein, inter alia, are compositions of organic acid-producing microorganisms and methods of making and using the same to inhibit pathogenic bacterial populations in the gastrointestinal tracts of an animal and additionally promote improvement of one or more metrics in an animal, such as increased bodyweight gain, decreased feed conversion ratio (FCR), improved gut barrier integrity, reduced mortality, reduced pathogen infection, and reduced pathogen shedding in feces.

A vaginitis pathogen-inhibiting composition comprises a fermentate of lactic acid bacteria, which is generated by jointly fermenting a lactic acid bacteria strain and Streptococcus thermophilus in a medium containing at least one of milk, powdered milk, and casein. The lactic acid bacteria strain includes an AP-32 strain of Lactobacillus salivarius subsp. Salicinius; an F-1 strain of Lactobacillus rhamnosus; a GL-165 strain of Lactobacillus rhamnosus; a CP-9 strain of Bifidobacterium animalis subsp. lactis; a Bf-688 strain of Bifidobacterium bifidum; a Bv-889 strain of Bifidobacterium breve; or combinations thereof. The above-mentioned fermentate of the lactic acid bacteria strain can inhibit growth of vaginitis pathogens and may be in form of a food composition, a pharmaceutical composition, or a vagina-cleaning composition.

The present invention provides a composition for promoting glucolipid metabolism, and a preparation and an application thereof, and relates to the technical field of probiotics. The composition of the present invention includes probiotics and inulin; the probiotics include Bifidobacterium longum, Bifidobacterium breve, Lactobacillus gasseri, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus cripatus, Lactobacillus plantarum, Lactobacillus fermentum, and Lactobacillus casei. In the composition of the present invention, the nine strains synergize with each other, which function as a regulator of glucolipid metabolism, improve sensitivity to insulin receptor in the body, and relieve insulin resistance when reconstituted with inulin. The composition has some effects on improving serum total cholesterol and triglyceride, islet -cell function, and type 2 diabetes mellitus.

The present invention provides a composition for promoting glucolipid metabolism, and a preparation and an application thereof, and relates to the technical field of probiotics. The composition of the present invention includes probiotics and inulin; the probiotics include Bifidobacterium longum, Bifidobacterium breve, Lactobacillus gasseri, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus cripatus, Lactobacillus plantarum, Lactobacillus fermentum, and Lactobacillus casei. In the composition of the present invention, the nine strains synergize with each other, which function as a regulator of glucolipid metabolism, improve sensitivity to insulin receptor in the body, and relieve insulin resistance when reconstituted with inulin. The composition has some effects on improving serum total cholesterol and triglyceride, islet -cell function, and type 2 diabetes mellitus.

A strain of Lactobacillus salivarius as a probiotic product, and its use in the treatment and/or prevention of otitis and upper respiratory infections.

A food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose are provided, comprising an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including a GL-104 strain of Lactobacillus reuteri (CCTCC NO: M209138), an AP-32 strain of Lactobacillus salivarius subsp. salicinius (CCTCC NO: M2011127), a TYCA06 strain of Lactobacillus acidophilus (CGMCC No: 15210), and an MH-68 strain of Lactobacillus johnsonii (CCTCC NO: M2011128), or a combination thereof.

A food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose are provided, comprising an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including a GL-104 strain of Lactobacillus reuteri (CCTCC NO: M209138), an AP-32 strain of Lactobacillus salivarius subsp. salicinius (CCTCC NO: M2011127), a TYCA06 strain of Lactobacillus acidophilus (CGMCC No: 15210), and an MH-68 strain of Lactobacillus johnsonii (CCTCC NO: M2011128), or a combination thereof.

Lactobacillus-based probiotic compositions for inclusion in microbial-based products. In one instance, the microbial-based product takes the form of an animal feed additive. When used as a feed additive for animals, especially ruminants, and in particular cattle, the following benefits from the composition are noted: (i) improved milk yield in dairy cattle, (ii) improved milk composition in dairy cattle, (iii) increased weight gain-to-feed intake ratio in beef cattle (feed efficiency), and (vi) improved average daily weight gain. Both Lactobacillus strains MB101 having ATCC Accession Number PTA-121710 and MB102 having ATCC Accession Number PTA-121711 are particularly effective at producing these results. Another marked benefit of the compositions when used as an animal feed additive is inhibition of pathogenic growth including E. coli, Salmonella, Clostridium, Staphylococcus and Streptococcus.

The invention relates to a dry compositions for lactic acid bacteria and in particular to a dry composition comprising from 10.sup.9 to 10.sup.13 cfu/g of the composition of lactic acid bacteria cells, wherein the composition is characterized by that it also comprises following amounts of protective agents (all amounts of protective agents below are given relative to 1 g of lactic acid bacteria cells in the composition): from 6 to 9 g of trehalose, from 0.1 to 1 g of inulin and from 0.5 to 3 g of hydrolyzed casein, and by that it does not comprise a salt of alginic acid. The composition has an improved storage stability of the cell of interest. Comparison experiments have been made between compositions with and without alginate and it has been found that there is substantially no difference between compositions with or without alginate with regard to stability. Further, the invention relates to a method for preparing a dry lactic acid bacteria composition.

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure.